Orasi Medical Partners to Improve Neurological Drug Development

MINNEAPOLIS, MN, Sep 09, 2010 (MARKETWIRE via COMTEX) -- Orasi Medical(R), today announced that it has entered an agreement with Novartis Pharmaceuticals Corporation (Novartis) to develop a novel central nervous system (CNS) biomarker.

Under the agreement, Novartis will utilize Orasi Index(TM) Orasi Medical's key product, to develop a new CNS biomarker to support measurement of disease and treatment effect. The companies will collaborate to identify and develop a biomarker through the use of magnetoencephalography (MEG). Orasi Medical develops neurological biomarkers based on electrical activity of the brain and Orasi Index can accelerate drug development, reduce costs and improve CNS drug innovation by accurately measuring neurological drug effects and real-time brain function throughout key phases of the drug development process.

"We are quite pleased that Novartis will utilize Orasi Index to develop more effective drugs for the many people affected by CNS diseases," said Shawn Lyndon, Chief Executive Officer of Orasi Medical. "We look forward to working with Novartis on this innovative project, and similar collaborations in the future."

About Orasi Medical

Orasi Medical develops products to measure the effect of neurological treatments and track the progression of neurological disorders. Pharmaceutical companies use Orasi Index(TM), the company's flagship product, to reduce costs and improve clinical development of neurological treatments. Orasi's high-resolution measurement of brain function provides a robust, non-invasive and reproducible measure of pharmacodynamics and treatment effect and its software as a service model enables highly efficient web-based analysis and reporting of the results. For more information, please visit www.orasimedical.com

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.